LEADER 04616nam  2200589Ia 450 
001 9910452895703321
005 20200520144314.0
010   $a1-61942-351-0
035   $a(CKB)2550000001040604
035   $a(EBL)3017734
035   $a(SSID)ssj0001047813
035   $a(PQKBManifestationID)11623052
035   $a(PQKBTitleCode)TC0001047813
035   $a(PQKBWorkID)11159081
035   $a(PQKB)10855794
035   $a(MiAaPQ)EBC3017734
035   $a(Au-PeEL)EBL3017734
035   $a(CaPaEBR)ebr10654705
035   $a(OCoLC)923653492
035   $a(EXLCZ)992550000001040604
100   $a20120130d2012      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aAcute rejection$b[electronic resource] $erisk factors, management and complications /$fTakumi Kobayashi, Riku Arai, editors
210   $aHauppauge, NY $cNova Science Publishers, Inc.$d2012
215   $a1 online resource (211 p.)
225 0 $aImmunology and immune system disorders
300   $aDescription based upon print version of record.
311   $a1-61942-346-4 
320   $aIncludes bibliographical references and index.
327   $a""ACUTE REJECTION: RISK FACTORS, MANAGEMENT AND COMPLICATIONS""; ""ACUTE REJECTION: RISK FACTORS, MANAGEMENT AND COMPLICATIONS""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""Chapter 1: HLA and Non-HLA Genes Polymorphisms: Susceptibility  and Severity in Tunisian Patients  with Rheumatoid Arthritis""; ""Abstract""; ""1. Introduction""; ""2. Evaluation of Genetic Predisposition to RA""; ""2.1. Prevalence of RA""; ""2.2. Familial Clustering Studies""; ""2.3. Twins Studies""; ""3. Identification of Candidate Genes""; ""3.1. Linkage Studies""
327   $a""3.2. Candidate Gene Association Studies""""4. Results of Linkage Studies in RA""; ""5. HLA Association With RA""; ""6. Non HLA Candidate Genes  Case-control Studies""; ""6.1. Protein Tyrosine Phosphatase Non-Receptor, Type 22 (PTPN22)""; ""6.2. Tumor Necrosis Factor Receptor Type 2 (TNF-R2)""; ""6.3. Peptidyl Arginine Deiminase 4 (PADI 4)""; ""6.4. Fc I?³ Receptor IIIa (FcI?³RIIIa)""; ""6.5. Interleukin 1 Receptor Antagonist (IL-1Ra)""; ""6.6. Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4)""; ""6.7. Apo-1/Fas (CD95)""; ""6.8. Adhesion Molecules""; ""7. Patients and Methods""
327   $a""7.1. Patients and Controls""""7.2. Methods""; ""7.3. Statistical Methods""; ""8. Results""; ""8.1. HLA Typing""; ""a/ DRB1 Genotyping""; ""b/ DRB1*04 Sub-typing""; ""8.2. PTPN22 Genotyping""; ""8.3. CTLA-4 Genotyping""; ""8.4. Apo-1/Fas Genotyping""; ""8.5. FcI?³R Genotyping""; ""8.6. Adhesion Molecules Genotyping""; ""8.7. IL1 Family Polymorphisms Genotyping""; ""a/ IL1I?± (C/T -889)""; ""b/ IL1Ra (Intron 2)""; ""c/ IL1I?² C/T -511 and C/T +3954""; ""9. Discussion""; ""Conclusion""; ""Acknowledgment""; ""References""
327   $a""Chapter 2: Mechanisms, Management  and Consequences of Acute  Cellular and Antibody Mediated Rejection in Solid Organ and Reconstructive Transplantation""""Abstract""; ""1. Acute Rejection""; ""2. Kidney Transplantation""; ""2.1 The Banff Classification""; ""2.2 Acute Antibody-Mediated Rejection in Kidney Transplantation""; ""2.3 Acute T-Cell-Mediated Rejection in Kidney Transplantation""; ""2.3.1. Steps in TCMR a??? 3 Signals [12]""; ""3. Pancreas Transplantation""; ""3.1 The Banff Classification""; ""3.2 Acute Antibody-Mediated Rejection in Pancreas Transplantation""
327   $a""3.3 Acute T-Cell-Mediated Rejection in Pancreas Transplantation""""4. Liver Transplantation""; ""4.1 Banff Schema for Grading of Liver Allograft Rejection""; ""4.2 Acute Antibody-Mediated Rejection in Liver Transplantation""; ""4.3 Acute T-Cell-Mediated Rejection in Liver Transplantation""; ""5. Intestinal and Multivisceral Transplantation""; ""5.2 Acute Antibody-Mediated Rejection  in Intestinal Transplantation""; ""5.3 Acute T-Cell-Mediated Rejection  in Intestinal Transplantation""; ""6. Vascularized Composite Allotransplantation""
327   $a""6.1 Banff Classification of Skin-Containing Composite  Tissue Allografts""
410  0$aImmunology and Immune System Disorders
606   $aGraft rejection
606   $aTransplantation immunology
608   $aElectronic books.
615  0$aGraft rejection.
615  0$aTransplantation immunology.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910452895703321
996   $aAcute rejection$92170161
997   $aUNINA